Recent studies from Australia and Europe suggest bempedoic acid may be more cost effective compared to statins [54,55]. Considering the above-mentioned benefits, bempedoic acid should be explored as an additional therapy to achieve required LDL-C levels in statin-intolerant patients [54,55]. Chall...
Bempedoic acid (ETC-1002),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an
725 Cost Effectiveness of Bempedoic Acid for Those at High Risk Cardiovascular Diseasedoi:10.1016/j.hlc.2020.09.732K. PereraN. KamZ. AdemiD. LiewE. ZomerHeart, Lung and Circulation
Objective: To examine the cost-effectiveness of a newly approved combination of bempedoic acid and ezetimibe (BAEze) in patients with ASCVD from a U.S. healthcare sector perspective. Methods: State-transition Markov model of US adults with ASCVD and low-density lipoprotein cholesterol (LDL-C) ...
Bempedoic acidCost-effectivenessCardiovascular diseaseLipid-loweringPreventionBACKGROUND: Bempedoic acid is a novel adenosine triphosphate citrate lyase inhibitor shown to reduce low density lipoprotein cholesterol when used as an adjunct lipid-lowering therapy in patients with high cardiovascular disease (CVD)...
As a result the need for PCSK9 inhibitors (PCSK9i) is projected to increase significantly, with a concomitant substantial impact on treatment cost. Adding the novel lipid lowering agent bempedoic acid (BA) to established oral lipid lowering therapy could provide an affordable alternative to PCSK9...
Unfortunately, some of these strategies remain expensive, such as the use of proprotein convertase subtilisin/kexin type 9 inhibitors, thus new agents with more affordable cost/effectiveness ratio are welcome. Bempedoic acid is an interesting new opportunity to manage the complex scenario of ...